487 results match your criteria Nature Clinical Practice Rheumatology [Journal]


New approaches for managing antiphospholipid syndrome.

Nat Clin Pract Rheumatol 2009 Mar;5(3):160-70

The Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA.

Antiphospholipid antibodies (aPL) are a family of autoantibodies directed against phospholipid-binding plasma proteins, most commonly beta(2)-glycoprotein-I. Primary thrombosis prevention in persistently aPL-positive individuals requires a risk-stratified approach; elimination of reversible thrombosis risk factors and aggressive prophylaxis during high-risk periods are crucial. The effectiveness of aspirin in persistently aPL-positive patients without vascular involvement is not supported by data from prospective, controlled studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1017DOI Listing
March 2009
5 Reads

Imaging the painful osteoarthritic knee joint: what have we learned?

Nat Clin Pract Rheumatol 2009 Mar;5(3):149-58

Department of Rheumatology, Leeds Teaching Hospitals Trust, UK.

Pain in the peripheral joints is an increasingly common problem, resulting in significant patient disability and health-care expenditure. Osteoarthritis (OA), a syndrome of joint pain with associated structural changes, is the most prevalent joint disease, yet the etiology of pain in OA is not entirely clear. Traditional assessment of the structure-pain relationship in knee OA has relied on conventional radiography, which has several limitations, not least the discrepancy between symptoms and radiographic findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1023DOI Listing
March 2009
2 Reads

Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside.

Nat Clin Pract Rheumatol 2009 Mar;5(3):139-48

Division of Rheumatology, New York Medical College, New York, NY, USA.

One of the strongest clinical associations with autoantibodies against components of the SSA/Ro-SSB/La ribonucleoprotein complex is the development of congenital heart block in an offspring, an alarming prospect facing 2% of primigravid mothers with these reactivities. This risk is increased tenfold in women who have had a previous child with congenital heart block. Accumulated evidence suggests that anti-SSA/Ro and anti-SSB/La antibodies are necessary but insufficient for fetal disease. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncprheum1018
Publisher Site
http://dx.doi.org/10.1038/ncprheum1018DOI Listing
March 2009
8 Reads

Time for new outcome measures in hand osteoarthritis?

Nat Clin Pract Rheumatol 2009 Mar;5(3):136-8

Rheumatology, Saint-Antoine Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1021DOI Listing
March 2009
3 Reads

Is spleen tyrosine kinase inhibition an effective therapy for patients with RA?

Nat Clin Pract Rheumatol 2009 Mar;5(3):130-1

Rheumatology and Immunology at University of Glasgow, Glasgow, UK.

Despite the success of biologic therapeutic agents that target cytokines and lymphocytes, clinical needs remain unmet in the treatment of rheumatoid arthritis (RA). The development of small-molecule inhibitors that can block critical immune signal-transduction pathways are of particular interest as novel therapies for RA. Spleen tyrosine kinase (SYK) subserves the function of Fc receptors and the B-cell receptor; as such, it is attractive as a potential therapeutic target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1025DOI Listing
March 2009
4 Reads

Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?

Nat Clin Pract Rheumatol 2009 Mar;5(3):128-9

Department of Rheumatology and Clinical Immunology at Charité-Universitätsmedizin Berlin, Germany.

The interleukin 6 receptor antagonist tocilizumab was investigated in a 24-week, phase III randomized controlled trial for the treatment of active, DMARD-resistant rheumatoid arthritis (TOWARD study). The results indicated that the combination of tocilizumab with standard DMARDs produced a significantly higher clinical response rate than DMARDs alone, according to American College of Rheumatology and European League Against Rheumatism response criteria. Evaluation of adverse events revealed that tocilizumab had a good safety profile, although a slightly increased rate of infections, neutropenia, elevated liver enzyme levels and increased lipid levels were observed in some individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1005DOI Listing
March 2009
5 Reads

How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?

Authors:
Peter C Taylor

Nat Clin Pract Rheumatol 2009 Mar;5(3):126-7

Experimental Rheumatology at Kennedy Institute of Rheumatology Division, Imperial College, London, UK.

Since the introduction of biologic therapies that target tumor necrosis factor (TNF), short-term and long-term outlooks for many patients with rheumatoid arthritis have greatly improved. Not all patients, however, respond to therapy with these agents. Furthermore, despite favorable overall profiles for safety and tolerability, some concerns remain in this regard. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1022DOI Listing
March 2009
7 Reads

Is arthroscopic surgery a beneficial treatment for knee osteoarthritis?

Authors:
Richard W Nutton

Nat Clin Pract Rheumatol 2009 Mar;5(3):122-3

Orthopedics and Trauma at University of Edinburgh, Edinburgh, UK.

Considering the high prevalence of knee osteoarthritis and the relatively common use of arthroscopy to treat this condition, few well-designed studies have been published on the effectiveness of arthroscopy for treating knee osteoarthritis. The study by Kirkley et al. is a welcome addition to the literature as it addresses many of the criticisms of previous work by using appropriate exclusion criteria, standardizing treatment in the study groups, using well-validated clinical scores, and providing a period of follow-up exceeding 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1020DOI Listing
March 2009
4 Reads

Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP.

Nat Clin Pract Rheumatol 2009 Mar;5(3):120-1

University of New Mexico School of Medicine and Osteoporosis and New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM 87106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1024DOI Listing
March 2009
4 Reads

Available therapeutic options following failure of a first anti-TNF agent.

Authors:
Alan J Silman

Nat Clin Pract Rheumatol 2009 Mar;5(3):115

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1028DOI Listing
March 2009
7 Reads

Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis.

Nat Clin Pract Rheumatol 2009 Mar 3;5(3):171-3. Epub 2009 Feb 3.

Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada.

Background: A 49-year-old man presented to a rheumatology clinic with a 2-month history of low back pain. The pain seemed to be inflammatory in origin, with nocturnal occurrence and substantial early morning stiffness. The patient was previously well, with no history of psoriasis, inflammatory bowel disease or iritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1003DOI Listing
March 2009
5 Reads

Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?

Authors:
Daniel E Furst

Nat Clin Pract Rheumatol 2009 Mar 3;5(3):134-5. Epub 2009 Feb 3.

Rheumatology at Geffen School of Medicine at UCLA, CA 90095-1670, USA.

The efficacy and safety of a new tumor necrosis factor inhibitor, certolizumab pegol, in active rheumatoid arthritis has now been assessed in three phase III, multicenter, randomized, double-blind, placebo-controlled clinical trials. This commentary focuses on the paper by Keystone et al., in which patients were followed for the longest duration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1004DOI Listing
March 2009
5 Reads

A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis.

Nat Clin Pract Rheumatol 2009 Mar 3;5(3):132-3. Epub 2009 Feb 3.

Rheumatology at Guy's and St Thomas' NHS Foundation Trust, London, UK.

There is a clear need for both disease-modifying agents and alternative analgesic therapies in osteoarthritis. Currently, there are none of the former, and the latter are limited by adverse effects, particularly gastrointestinal and cardiovascular effects. A new class of analgesic agent that is under investigation inhibits 5-lipoxygenase (5-LOX), the enzyme that catalyzes the conversion of membrane-bound arachidonic acid to leukotrienes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1006DOI Listing
March 2009
4 Reads

Are static resting wrist splints beneficial in early RA?

Nat Clin Pract Rheumatol 2009 Mar;5(3):124-5

Department of Orthopaedics at Leiden University Medical Center, Leiden, The Netherlands.

In a randomized controlled trial, Adams et al. compared the effectiveness of static resting wrist splints plus occupational therapy with occupational therapy alone in 120 patients with early rheumatoid arthritis. Self-reported adherence with splint wear was moderate, with 24. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum1007DOI Listing
March 2009
3 Reads

Neurocognitive impairment in children and adolescents with systemic lupus erythematosus.

Nat Clin Pract Rheumatol 2009 Feb;5(2):106-14

Division of Rheumatology, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY, USA.

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, in which neuropsychiatric manifestations are a common cause of significant morbidity. The American College of Rheumatology has identified 19 distinct neuropsychiatric syndromes associated with SLE, although the 1982 American College of Rheumatology classification criteria for SLE recognize only two: seizures and psychosis. Neurocognitive impairment (NCI) is one of the most common and clinically challenging manifestations of SLE, but its pathophysiology remains poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918878PMC
February 2009
2 Reads

The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease.

Nat Clin Pract Rheumatol 2009 Feb;5(2):99-105

Be'er Ya'akov Mental Health Center, Be'er Ya'akov, Israel.

Melanin has several physiological roles in maintaining health, but, notably, it affects the synthesis of vitamin D. Melanin is the primary determinant of the degree of skin pigmentation and protects the body from harmful ultraviolet radiation. Synthesis of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) in the skin, however, is dependent on ultraviolet B light. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0989DOI Listing
February 2009
5 Reads

Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative.

Nat Clin Pract Rheumatol 2009 Feb;5(2):92-8

Sansom Institute of Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.

Inflammatory and injury-induced skeletal pain are common conditions, and both conventional nonselective NSAIDs and the newer cyclo-oxygenase-2-specific inhibitors are widely used as post-traumatic and post-surgical analgesics. However, new research suggests that these drugs, particularly the cyclo-oxygenase-2 inhibitors, have a negative effect on the healing process in fractured bone and within orthopedic surgical sites, thus highlighting a need to develop new approaches for managing skeletal pain. Various experimental studies have revealed that locally upregulated neurotrophic factors, especially nerve growth factor, have a major role in mediating injury-induced or inflammatory pain. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncprheum0982
Publisher Site
http://dx.doi.org/10.1038/ncprheum0982DOI Listing
February 2009
8 Reads

New insights into the pathogenesis and genetics of psoriatic arthritis.

Nat Clin Pract Rheumatol 2009 Feb;5(2):83-91

Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA.

Psoriasis vulgaris and psoriatic arthritis (PsA) are inter-related heritable diseases. Psoriatic skin is characterized by hyperproliferative, poorly differentiated keratinocytes and severe inflammation. Psoriatic joints are characterized by highly inflamed synovia and entheses with focal erosions of cartilage and bone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790861PMC
February 2009
11 Reads

Imaging in osteoarthritis trials: useful or just expensive?

Nat Clin Pract Rheumatol 2009 Feb;5(2):76-7

Osteoarthritis Research Unit, Notre-Dame Hospital, Research Centre of theUniversity of Montreal, Hospital Centre (CR-CHUM), 1560 Sherbrooke Street East, Montréal, QC H2L 4M1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0990DOI Listing
February 2009
8 Reads

Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?

Nat Clin Pract Rheumatol 2009 Feb;5(2):74-5

Department of Rheumatology, 3A61 Vrije Universiteit Medical Center, Postbox 7057, 1007 MB Amsterdam, The Netherlands.

Few data are available on the prevention of fracture in glucocorticoid-treated premenopausal women with autoimmune disorders such as systemic lupus erythematosus. In this setting, Okada et al. compared the effect of coadministration of alfacalcidol alone with that of alfacalcidol combined with alendronate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0991DOI Listing
February 2009
5 Reads

Are statins useful for treating vascular involvement in systemic sclerosis?

Nat Clin Pract Rheumatol 2009 Feb;5(2):70-1

Department of Biomedicine, Reference Center for Systemic Sclerosis, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Research suggests that statins could be useful to treat vascular manifestations related to systemic sclerosis, but data on their potential clinical benefits remain limited. Previous studies suggested that statins increase the number of circulating endothelial precursor cells, and thereby improve the severity of Raynaud's phenomenon. Abou-Raya et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0993DOI Listing
February 2009
4 Reads

The uncertain pathway to new therapeutics for SLE.

Authors:
Peter E Lipsky

Nat Clin Pract Rheumatol 2009 Feb;5(2):61

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0992DOI Listing
February 2009
5 Reads

RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists.

Authors:
Ernest Choy

Nat Clin Pract Rheumatol 2009 Feb 23;5(2):66-7. Epub 2008 Dec 23.

Academic Department of Rheumatology, King's College London, London, UK.

Over the last decade, the use of tumor necrosis factor (TNF) inhibitors has improved the prognosis of patients with rheumatoid arthritis. Although these agents are more efficacious than traditional DMARDs, a substantial proportion of patients discontinue anti-TNF therapy because of adverse effects or lack of efficacy. Therapeutic options for these patients include dose increases, switching to an alternative TNF antagonist, or switching to a biologic of a different class, such as rituximab or abatacept. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0984DOI Listing
February 2009
9 Reads

Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.

Nat Clin Pract Rheumatol 2009 Feb 23;5(2):78-9. Epub 2008 Dec 23.

Department of Medical Decision Making, Leiden University Medical Centre, Leiden, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0985DOI Listing
February 2009
4 Reads

A case of childhood-onset ankylosing spondylitis: diagnosis and treatment.

Nat Clin Pract Rheumatol 2009 Jan;5(1):52-7

Rheumatology Department, Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Background: A 14-year-old boy with a 6-year history of recurrent arthritis and enthesitis, which had not responded to previous treatment with NSAIDs, sulfasalazine and methotrexate, presented with a severe flare of these symptoms as well as spinal and sacroiliac joint pain. The patient's father had mild psoriasis.

Investigations: Counts of tender and swollen joints and tender entheses; assessment of spinal mobility; assessments using the Childhood Health Assessment Questionnaire and the Bath Ankylosing Spondylitis Disease Activity and Functional Indices; measurement of erythrocyte sedimentation rate, serum C-reactive protein level and human leukocyte antigen B27 positivity; radiographs of the sacroiliac joints, hips and feet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0971DOI Listing
January 2009
4 Reads

There's more to life than everyday function: the challenge of measuring social role participation in ankylosing spondylitis.

Nat Clin Pract Rheumatol 2009 Jan;5(1):46-51

Toronto Western Research Institute, Toronto, ON, Canada.

Symptoms and functional limitations are commonly reported primary outcome measures in ankylosing spondylitis (AS); however, participation has not been widely evaluated, as reflected by the scarcity of literature on the subject. People with AS suggest that participation in social roles (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0978DOI Listing
January 2009
4 Reads

The role of ADAMTS-7 and ADAMTS-12 in the pathogenesis of arthritis.

Authors:
Chuan-Ju Liu

Nat Clin Pract Rheumatol 2009 Jan;5(1):38-45

New York University School of Medicine, New York, NY 10003, USA.

Loss of articular cartilage caused by extracellular matrix breakdown is the hallmark of arthritis. Degradative fragments of cartilage oligomeric matrix protein (COMP) have been observed in arthritic patients. ADAMTS-7 and ADAMTS-12, two members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family, have been associated with COMP degradation in vitro, and are significantly overexpressed in the cartilage and synovium of patients with rheumatoid arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433145PMC
January 2009
2 Reads

The molecular basis of pain and its clinical implications in rheumatology.

Nat Clin Pract Rheumatol 2009 Jan;5(1):28-37

Wyeth Research, Princeton, NJ 08543-8000, USA.

Nociceptive pain in response to peripheral noxious stimuli, and inflammatory pain resulting from tissue damage, serve as warnings that normal bodily function cannot resume until the stimulus abates or the tissue repairs. Stimuli cause numerous receptors, ion channels and other cellular machinery to respond, and propagate signals to the central nervous system, where this information is processed and perceived as pain. In healthy individuals, tissue damage results in physiologic--generally reparative--changes that lead to heightened sensory perception and, often, pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0972DOI Listing
January 2009
7 Reads

Potential new drug targets for osteoporosis.

Authors:
Chad Deal

Nat Clin Pract Rheumatol 2009 Jan;5(1):20-7

Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, OH 44195, USA. [corrected]

Osteoporosis is a worldwide health problem with a high prevalence. Agents for the treatment of osteoporosis are classified as either antiresorptive or anabolic. Antiresorptive agents work by inhibiting the activity of osteoclasts and, therefore, reducing bone resorption. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncprheum0977
Publisher Site
http://dx.doi.org/10.1038/ncprheum0977DOI Listing
January 2009
6 Reads

Rheumatoid arthritis in a mouse?

Authors:
Gary S Firestein

Nat Clin Pract Rheumatol 2009 Jan;5(1)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754140PMC
January 2009
4 Reads

Is there a role for everolimus in the treatment of RA?

Authors:
Nancy J Olsen

Nat Clin Pract Rheumatol 2009 Feb 17;5(2):68-9. Epub 2008 Dec 17.

Rheumatic Diseases Division, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8884, USA.

The past decade has seen remarkable advances in the treatment of rheumatoid arthritis. Although this is good news for the majority of patients, one consequence is that the environment for the development of new drugs has become difficult as a result of high expectations for efficacy. Nevertheless, there remains a subgroup of patients with rheumatoid arthritis who are not candidates for treatment with the newer biologic agents and in whom oral DMARDs have certain advantages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0980DOI Listing
February 2009
2 Reads

Is denosumab better than alendronate in the treatment of osteoporosis?

Nat Clin Pract Rheumatol 2009 Feb 17;5(2):72-3. Epub 2008 Dec 17.

New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA.

Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand (RANKL), the principal mediator of osteoclastic bone resorption. By binding to RANKL, denosumab reduces the differentiation, activity and survival of osteoclasts, and thereby slows the rate of bone resorption. These antiresorptive effects led to the development of this agent as a treatment for osteoporosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0981DOI Listing
February 2009
5 Reads

Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells.

Authors:
Syamal K Datta

Nat Clin Pract Rheumatol 2009 Feb 17;5(2):80-2. Epub 2008 Dec 17.

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0983DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713746PMC
February 2009
6 Reads

Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?

Nat Clin Pract Rheumatol 2009 Jan 2;5(1):12-3. Epub 2008 Dec 2.

Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0962DOI Listing
January 2009
4 Reads

Inflammation, glucocorticoids and risk of cardiovascular disease.

Nat Clin Pract Rheumatol 2009 Jan 2;5(1):18-9. Epub 2008 Dec 2.

Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0963DOI Listing
January 2009
2 Reads

NICE guidelines on anti-tumor necrosis factor therapy for RA.

Nat Clin Pract Rheumatol 2009 Jan 2;5(1):16-7. Epub 2008 Dec 2.

Department of Rheumatology, King's College Hospital, London, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncprheum0964
Publisher Site
http://dx.doi.org/10.1038/ncprheum0964DOI Listing
January 2009
16 Reads

Activated B cells in autoimmune diseases: the case for a regulatory role.

Nat Clin Pract Rheumatol 2008 Dec;4(12):657-66

University of Edinburgh, Edinburgh, UK.

B lymphocytes contribute to immunity through organogenesis of secondary lymphoid organs, presentation of antigen to T cells, production of antibodies, and secretion of cytokines. Their roles in autoimmune diseases are complex. Clinical trials have shown that depleting B cells can significantly ameliorate such diseases, underlining the contributions of B cells to pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0950DOI Listing
December 2008
11 Reads

Mycobacterial disease in patients with rheumatic disease.

Nat Clin Pract Rheumatol 2008 Dec;4(12):649-56

Respiratory Diseases Department, Radboud University Nijmegen Medical Center, The Netherlands.

This Review focuses on the emergence of mycobacterial disease in patients undergoing treatment for rheumatic disease with four new drug classes--tumor necrosis factor (TNF) inhibitors, human interleukin (IL)-1 receptor antagonists, anti-CD20 antibodies and CD4(+) T-cell costimulation modulators--collectively referred to as biologic agents. Mycobacterial disease is a major cause of severe infection in patients undergoing anti-TNF therapy. Reports are now emerging of an association between mycobacterial infection and antirheumatic treatment with anti-IL-1 or anti-CD20 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0949DOI Listing
December 2008
15 Reads
9 Citations

Issues in the design of new clinical trials for rheumatoid arthritis therapeutics.

Nat Clin Pract Rheumatol 2008 Dec;4(12):641-8

Tekgenics, Inc., Mobile, AL 36619, USA.

Rheumatoid arthritis (RA) is a chronic, heterogeneous disease, for which there has traditionally been few reliable prognostic indicators or simple clinical outcome measures with which to adequately assess disease status or clinical improvement. These challenges have hindered the assessment of new therapeutic agents. Investigators in rheumatology have, therefore, attempted over the past two decades to develop new approaches and scoring systems to facilitate the study and development of therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0948DOI Listing
December 2008
4 Reads

A growing crisis in confidence.

Authors:
Peter E Lipsky

Nat Clin Pract Rheumatol 2008 Dec;4(12):621

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0957DOI Listing
December 2008
5 Reads

American College of Rheumatology recommendations for the treatment of RA: an issue of choices.

Nat Clin Pract Rheumatol 2009 Jan 25;5(1):8-9. Epub 2008 Nov 25.

Department of InternalMedicine/Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0958DOI Listing
January 2009
5 Reads

Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw.

Nat Clin Pract Rheumatol 2009 Jan 25;5(1):6-7. Epub 2008 Nov 25.

Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0960DOI Listing
January 2009
4 Reads

Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism.

Nat Clin Pract Rheumatol 2009 Jan 18;5(1):14-5. Epub 2008 Nov 18.

Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, University of Birmingham, Birmingham, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncprheum0959
Publisher Site
http://dx.doi.org/10.1038/ncprheum0959DOI Listing
January 2009
6 Reads

Painful knee locking caused by gouty tophi successfully treated with allopurinol.

Nat Clin Pract Rheumatol 2008 Dec 11;4(12):675-9. Epub 2008 Nov 11.

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH 44195, USA.

Background: A 67-year-old man presented to a rheumatology clinic with a 1-week history of severe pain and swelling of his right knee. He had been receiving allopurinol for about 5 months for the treatment of chronic gouty arthropathy of more than 30 years' duration. On examination, his right knee was warm and swollen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0945DOI Listing
December 2008
4 Reads

First pregabalin and now duloxetine for fibromyalgia syndrome: closer to a brave new world?

Nat Clin Pract Rheumatol 2008 Dec 4;4(12):636-7. Epub 2008 Nov 4.

Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN 37232-2681, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0938DOI Listing
December 2008
4 Reads

Genetics of osteoarthritis: early developmental clues to an old disease.

Nat Clin Pract Rheumatol 2008 Nov;4(11):563

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0935DOI Listing
November 2008
6 Reads

Etanercept for patients with RA: more is not always better.

Authors:
Joel M Kremer

Nat Clin Pract Rheumatol 2009 Jan 28;5(1):10-1. Epub 2008 Oct 28.

Albany Medical College and Director of Research at The Center for Rheumatology in Albany, NY 12206, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0936DOI Listing
January 2009
4 Reads

The importance of recognizing scleroderma-type disorders in clinical practice.

Authors:
Laura K Hummers

Nat Clin Pract Rheumatol 2008 Dec 28;4(12):638-40. Epub 2008 Oct 28.

Johns Hopkins Scleroderma Center, Johns Hopkins University, Baltimore, MD 21224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0937DOI Listing
December 2008
4 Reads

Common mistakes in the clinical use of bone mineral density testing.

Nat Clin Pract Rheumatol 2008 Dec 21;4(12):667-74. Epub 2008 Oct 21.

New Mexico Clinical Research & Osteoporosis Center, University of New Mexico School of Medicine, Albuquerque, NM 87106, USA.

Bone mineral density (BMD) testing is used to diagnose osteoporosis, assess fracture risk and monitor changes in BMD over time. A variety of devices and technologies are used to measure BMD or other surrogate markers of bone strength. Measurements obtained with these devices are often reported according to different proprietary standards, and the comparability of values obtained with different instruments is often poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891842PMC
December 2008
4 Reads

Vitamin D and musculoskeletal health.

Nat Clin Pract Rheumatol 2008 Nov 14;4(11):580-8. Epub 2008 Oct 14.

Centracare Rheumatology Clinic, St Cloud, MN, USA.

Vitamin D is critical for calcium homeostasis. Following cutaneous synthesis or ingestion, vitamin D is metabolized to 25(OH)D and then to the active form 1,25(OH)2D. Low serum vitamin D levels are common in the general population and cause a decline in calcium absorption, leading to low serum levels of ionized calcium, which in turn trigger the release of parathyroid hormone, promoting skeletal resorption and, eventually, bone loss or osteomalacia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncprheum0921DOI Listing
November 2008
4 Reads